Research programme: hyperphosphataemia therapy - OPKO Health

Drug Profile

Research programme: hyperphosphataemia therapy - OPKO Health

Alternative Names: CTAA101 Capsules; CTAA102 Capsules

Latest Information Update: 08 Mar 2013

Price : $50

At a glance

  • Originator Cytochroma
  • Developer OPKO Health
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hyperphosphataemia

Most Recent Events

  • 04 Mar 2013 Cytochroma has been acquired by OPKO Health
  • 10 Jan 2007 Preclinical trials in Hyperphosphataemia in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top